AbCellera Biologics Inc. 8K

AbCellera Biologics Inc. reported Q2 2026 pipeline and financial updates, including new T-cell engager collaborations with Vertex and Jazz that bolster liquidity, continued clinical progress of multiple programs, a higher net loss on lower revenue, and the addition of two new independent directors to its board.

AbCellera Biologics Inc. provided a Q2 2026 business and financial update, highlighting clinical pipeline progress with completion of enrollment and dosing in its ABCL635 Phase 2 trial (top-line data expected in Q3 2026) and advancement of ABCL575 (Phase 1 top-line data expected in Q4 2026), ABCL688, and ABCL386 through IND-enabling activities, while also announcing two significant T-cell engager (TCE) collaboration agreements—one multi-target collaboration in autoimmunity and other conditions with Vertex Pharmaceuticals with $28 million in upfront payments plus potential downstream payments and royalties, and one oncology collaboration with Jazz Pharmaceuticals involving three discovery programs (with optional expansion to five) that provides $84 million in upfront payments (including $56 million received in Q2) and up to $2.5 billion in potential payments with tiered royalties. The company reported that recent TCE deals add $112 million in upfront cash to its balance sheet and that it maintained strong liquidity as of June 30, 2026, including approximately $565 million in total cash and marketable securities and about $110 million in available government funding, for roughly $675 million of available liquidity to support its strategy. AbCellera also reported Q2 2026 financial results, including revenue of $4.1 million (down from $17.1 million in Q2 2025), increased operating expenses reflecting higher R&D and SG&A spending, and a net loss of $55.4 million, or ($0.18) per basic and diluted share, and announced the appointment of Dr. Victor Sandor and Dr. Lynn Seely as new independent directors to its board of directors.

Filing Facts

CIK

1703057

Ticker

ABCL

Form

8K

Source Type

fda

Accession

0001703057-26-000044

Alert Tier

6